

July 29, 2010

Ei Yamada, President and Chief Executive Officer
AnGes MG, Inc.
(Code No.4563, TSE Mothers)
Contact: Fumihiko Suzuki, Director, Corporate Planning Dept.
Tel: +81-3-5730-2480

**EPS and AnGes Concluded a Comprehensive Business Alliance
Aiming to Explore for Business Expansion in China**

AnGes MG, Inc. ("AnGes") and EPS Co., Ltd. ("EPS") announced that they have signed a comprehensive partnership agreement to promote business expansion in China.

AnGes is aiming to develop and commercialize gene and oligonucleotide based drugs such as gene medicine, and has developed such products in Japan, the United States and Europe.

As for HGF gene medicine (product name: Collategene), NDA has been submitted for arteriosclerosis obliterans (severe limb ischemia) for marketing approval in Japan. In the U.S., AnGes has obtained a SPA (Special Protocol Assessment) agreement with the FDA, and the company is preparing for Phase III clinical trials.

AnGes' US partner company Vical Inc. (San Diego, California) is developing gene medicine (product name: Allovectin-7) for the metastatic malignant melanoma (metastatic melanoma) in North America and Europe, where many patients are suffering by the disease. The company has completed enrollment of Phase III clinical trials in January this year. AnGes has the exclusive rights for development and marketing Allovectin-7 in Japan and Asia, and owns the right to receive royalties on sales of U.S. and Europe as well.

In China, the higher growth rates in the pharmaceutical market was achieved in 2009, and Japanese companies are now focusing on a place of great opportunities. In particular, the tumor suppressor gene P53 gene medicine is already approved in China before any other part of the world. EPS has already established a Chinese subsidiary ten years ago, and has been promoting its business.

AnGes, considering the medical circumstances and environment in China, respects the achievements and experience of EPS's, and by establishing a comprehensive strategic partnership, AnGes wishes to develop and license out the rights of its product in China, in order to contribute to the improvement the QOL (Quality of Life) of patients in China.

The above facts will not cause any impact to AnGes' financials.

<Reference>

Company Name: EPS Co., Ltd.
Head Office: 2-23, Shimomiyabicho Shinjuku-ku, Tokyo
Representative: Yan Hao, President & CEO
Established: May 1991
Capital: 1,875.25 million yen
Number of Employees: 1,230 (a total of 2,825 in the group) *As of May 2010
Consolidated Sales: 23,568 million yen (term ending September 2009)
Scope of Business:

- Support services related to study/trial planning and protocol development
- Subject registration/allocation and progress management operations
- CRA operations (Monitoring)
- Data management and statistical analysis operations
- Medical device and instrument development services
- Safety information related operations
- QA/QC operations
- Regulatory application support operations
- Support operations for global development activities and imports/exports
- Data center management
- Contract development/marketing of softwares